Compare Vanguard Total Stock Market Index Fund ETF (VTI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Stock Market Index Fund ETF vs Viatris Inc — how do they compare? Vanguard Total Stock Market Index Fund ETF trades at $382 (market cap $2.30T), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 114.8× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Total Stock Market Index Fund ETF for 131 Days and Viatris Inc for 57 Days on average.
| VTI | VTRS | |
|---|---|---|
Market Cap | $2.30T | $20.03B |
Volume | 2,982,924 | 14,109,977 |
52-Week High | $384.30 | $18.27 |
52-Week Low | $311.68 | $9.74 |
Typical Hold Time | 131 Days | 57 Days |
Sector | — | Health |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTI trades at $381.94, up 0.24% on the day, with a bullish technical signal from moving averages. The ETF offers broad exposure to the U.S. stock market, though key valuation ratios like P/E and P/S are not provided in the current data. Recent news highlights its role in diversified portfolios and long-term growth potential, with a dividend scheduled for late September 2026.
The outlook for VTI is supported by its low-cost, diversified structure, appealing to long-term investors. Risks include market concentration in top holdings and overall equity market volatility. Analyst sentiment is generally positive, emphasizing its suitability for retirement and growth strategies amid current economic conditions.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
